Switch theme
Sign up to access all valuation multiples
HK Inno N Corp manufactures pharmaceutical products.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HK inno.N has a last 12-month revenue of $631M and a last 12-month EBITDA of $91.3M.
In the most recent fiscal year, HK inno.N achieved revenue of $611M and an EBITDA of $85.9M.
HK inno.N expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HK inno.N valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $565M | $611M | XXX | XXX | XXX |
| Gross Profit | $238M | $256M | XXX | XXX | XXX |
| Gross Margin | 42% | 42% | XXX | XXX | XXX |
| EBITDA | $69.9M | $85.9M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 14% | XXX | XXX | XXX |
| Net Profit | $26.0M | $32.2M | XXX | XXX | XXX |
| Net Margin | 5% | 5% | XXX | XXX | XXX |
| Net Debt | $233M | $219M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, HK inno.N's stock price is KRW 37000 (or $25).
HK inno.N has current market cap of KRW 1.05T (or $714M), and EV of KRW 1.40T (or $957M).
See HK inno.N trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $957M | $714M | XXX | XXX | XXX | XXX | $1.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, HK inno.N has market cap of $714M and EV of $957M.
HK inno.N's trades at 1.5x LTM EV/Revenue multiple, and 10.5x LTM EBITDA.
Analysts estimate HK inno.N's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for HK inno.N and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $957M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | XXX | XXX |
| P/E | 17.0x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | -70.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHK inno.N's NTM/LTM revenue growth is 10%
HK inno.N's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, HK inno.N's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate HK inno.N's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for HK inno.N and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HK inno.N acquired XXX companies to date.
Last acquisition by HK inno.N was XXXXXXXX, XXXXX XXXXX XXXXXX . HK inno.N acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is HK inno.N headquartered? | HK inno.N is headquartered in South Korea. |
| Who is the CEO of HK inno.N? | HK inno.N's CEO is Mr. Dal-Won Kwak. |
| Is HK inno.N publicy listed? | Yes, HK inno.N is a public company listed on KRX. |
| What is the stock symbol of HK inno.N? | HK inno.N trades under 195940 ticker. |
| When did HK inno.N go public? | HK inno.N went public in 2021. |
| Who are competitors of HK inno.N? | Similar companies to HK inno.N include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of HK inno.N? | HK inno.N's current market cap is $714M |
| What is the current revenue of HK inno.N? | HK inno.N's last 12-month revenue is $631M. |
| What is the current EBITDA of HK inno.N? | HK inno.N's last 12-month EBITDA is $91.3M. |
| What is the current EV/Revenue multiple of HK inno.N? | Current revenue multiple of HK inno.N is 1.5x. |
| What is the current EV/EBITDA multiple of HK inno.N? | Current EBITDA multiple of HK inno.N is 10.5x. |
| What is the current revenue growth of HK inno.N? | HK inno.N revenue growth between 2023 and 2024 was 8%. |
| Is HK inno.N profitable? | Yes, HK inno.N is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
